News

Filter

Current filters:

ResearchOncology

1 to 9 of 966 results

Foundation Medicine and H3 Biomedicine announce oncology collaboration

Foundation Medicine and H3 Biomedicine announce oncology collaboration

23-02-2015

USA-based Foundation Medicine and privately-held US biopharma company H3 Biomedicine have announced a…

BiotechnologyFoundation MedicineH3 BiomedicineOncologyResearchUSA

Merck Serono and Sysmex Inostics open first liquid biopsy RAS biomarker testing center

Merck Serono and Sysmex Inostics open first liquid biopsy RAS biomarker testing center

20-02-2015

Merck Serono, the biopharmaceutical business of Germany’s Merck KGaA, announced today that the first…

Merck KGaAMerck SeronoOncologyPharmaceuticalResearchSpainSysmex Inostics

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Cynata Therapeutics to begin scaling up its 'revolutionary' therapeutic stem cell technology

Cynata Therapeutics to begin scaling up its 'revolutionary' therapeutic stem cell technology

19-02-2015

Australian stem cell company Cynata Therapeutics is set to scale up manufacturing of its mesenchymal…

AustraliaBiotechnologyCymerusCynata TherapeuticsGeneticsMesenchymal stem cellOncologyProductionResearch

VBL Therapeutics shares slide as it ends VB-201 development in two indications

VBL Therapeutics shares slide as it ends VB-201 development in two indications

18-02-2015

Shares in Israeli drugmaker VBL Therapeutics dropped up to 55% after it said that it would discontinue…

Gastro-intestinalsIsraelOncologyPharmaceuticalResearchVBL Therapeutics

Positive Ph III results for Navidea’s Lymphoseek in head and neck cancer

17-02-2015

US biotech firm Navidea Biopharmaceuticals today announced positive peer-reviewed publication of results…

BiotechnologyLymphoseekNavidea BiopharmaceuticalsOncologyResearch

Takeda motesanib fails to meet primary endpoint in Ph III NSCLC study

Takeda motesanib fails to meet primary endpoint in Ph III NSCLC study

17-02-2015

In a second research negative this month, Japan’s largest drugmaker Takeda Pharmaceutical has today…

JapanmotesanibOncologyPharmaceuticalResearchTakeda Pharmaceutical

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

16-02-2015

UK-based medtech company Angle has raised £7.3 million ($11.2 million) through issuing new shares. It…

AngleBiotechnologyErbituxFinancialOncologyResearch

1 to 9 of 966 results

COMPANY SPOTLIGHT

Menarini

Back to top